Compare iShares MSCI Japan ETF (EWJ) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Summit Therapeutics Inc — how do they compare? iShares MSCI Japan ETF trades at $97.88 (market cap $23.87B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: iShares MSCI Japan ETF is the larger of the two by market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and Summit Therapeutics Inc for 16 Days on average.
| EWJ | SMMT | |
|---|---|---|
Market Cap | $23.87B | $13.71B |
Volume | 5,412,820 | 6,173,057 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $26.38 |
52-Week Low | $78.36 | $12.43 |
Typical Hold Time | 56 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.76, down 0.57% on the day amid mixed technical signals with a neutral overall rating. The ETF faces headwinds from Japan's monetary policy uncertainty as the Bank of Japan continues its tightening cycle, while benefiting from international equity outperformance trends in 2026. Technical indicators show the ETF trading near pivot point resistance at $98 with support at $97.
The outlook remains balanced with potential upside from Japan's AI and semiconductor exposure offset by currency volatility and rising bond yields. Key risks include yen fluctuations and global rate pressures, while institutional interest in Japanese equities provides support. The ETF's performance will hinge on BOJ policy effectiveness and sustained international market strength.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
